Keywords
viral load
HIV antibodies
immunoassay
transgender persons
highly active antiretroviral therapy
How to Cite
Abstract
HIV prevalence among travestis and transgender women (TrTW) is disproportionately higher when compared to the overall Brazilian population. The objective of this study was to evaluate, through conventional serological and molecular tests for the diagnosis of HIV infection, blood samples of TrTW residents of five Brazilian capitals with previous reactive HIV point-of-care rapid tests (RT). A total of 435 samples with at least one reactive HIV result on point-of-care tests were sent to the HIV reference laboratory in São Paulo State – the Adolfo Lutz Institute – for further evaluation by conventional laboratory tests. From total, 432 (99.3%) samples were reactive for HIV infection in conventional laboratory assays, comprising 98/432 (22.7%) with HIV-1 viral load over 5,000 copies/ml, and 334/432 (77.3%) reactive to serological tests (chemiluminescence immunoassay or ELISA, and rapid immunoblotting). The three remaining samples (0.7%) were classified as “indeterminate for HIV” based on conventional serological and molecular assays. Analytical sensitivity of different molecular and serological assays used in this study may have varied due to HIV-1 viral suppression resulting from antiretroviral therapy (ART). Additional studies are needed to better understand the impact of therapy on HIV diagnosis.
References
Magno L, Silva LAV, Vera MA, Santos MP, Dourado I. Stigma and discrimination related to gender identity and vulnerability to HIV/AIDS among transgender women: A systematic review. Cad Saúde Pública. 2019; 35(4): e00112718. https://doi.org/10.1590/0102-311X00112718
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: A systematic review and meta-analysis. Lancet Infect Dis. 2013; 13(3): 214-22. https://doi.org/10.1016/S1473-3099(12)70315-8
Coelho LE, Torres TS, Veloso VG, Grinsztejn B, Jalil EM, Wilson EC et al. The prevalence of HIV among men who have sex with men (MSM) and young MSM in Latin America and the Caribbean: A systematic review. AIDS Behav. 2021; 25(10): 3223-37. https://doi.org/10.1007/s10461-021-03180-5
Kerr L, Kendall C, Guimarães MDC, Mota RS, Veras MA, Dourado I et al. HIV prevalence among men who have sex with men in Brazil: Results of the 2nd national survey using respondent-driven sampling. Medicine. 2018; 97 (1S): S9-S15. https://doi.org/10.1097/MD.0000000000010573
Wilson EC, Jalil EM, Jalil CM, Castro CRV, Ferreira ALN, Martinez NF et al. Results from a peer-based digital systems navigation intervention to increase HIV prevention and care behaviors of young trans women in Rio de Janeiro, Brazil. J Glob Health. 2021; 5: e2021077. https://doi.org/10.29392/001c.28347
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico HIV/Aids 2020. [Internet]. 2020. [Acesso em: 2021, nov 18]. Disponível em: https://www.gov.br/saude/pt-br/assuntos/media/pdf/2020/dezembro/01/boletim-hiv_aids-2020
Parekh BS, Ou C-Y, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A et al. Diagnosis of human immunodeficiency virus infection. Clin Microbiol Rev. 2019; 32(1): e00064-18. https://doi.org/10.1128/CMR.00064-18
Brasil. Ministério da Saúde. Portaria SVS/MS Nº 29, de 17 de dezembro de 2013. Aprova o Manual técnico para o diagnóstico da infecção pelo HIV em adultos e crianças e dá outras providências. Diário Oficial da União. 18 dez 2013; Seção 1:59.
Castejon MJ, Dordetto PR, Yamashiro R, Brígido LFM, Alves AA, Oliveira CAF. Antiretroviral therapy in patient living with HIV leads negative HIV serological results. J Bras Patol Med Lab. 2021; 57(1):1-6. https://doi.org/10.5935/1676-2444.20210057
Bongertz V, Ouverney EP, Fernandez SC, Grinsztejn B, Veloso V, Couto-Fernandez JC et al. Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment. Mem Inst Oswaldo Cruz. 2007; 102(7): 817-25. https://doi.org/10.1590/S0074-02762007005000119
Killian MS, Norris PJ, Rawal BD, Lebedeva M, Hecht FM, Levy JA et al. The effects of early antiretroviral therapy and its discontinuation on the HIV specific antibody response. AIDS Res Hum Retroviruses. 2006; 22(7): 640-7. https://doi.org/10.1089/aid.2006.22.640
Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005; 192(2): 296-302. https://doi.org/10.1086/430922
Stefic K, Novelli S, Mahjoub N, Seng R, Molina J-M, Cheneau C et al. Nonreactive human immunodeficiency virus type 1 rapid tests after sustained viral suppression following antiretroviral therapy initiation during primary infection. J Infect Dis. 2018; 217(11): 1793-7. https://doi.org/10.1093/infdis/jiy120
Stoffels K, Vanroye F, Mortier V, Debaisieux L, Delforge M-L, Depypere M et al. Chronic and early antiretroviral therapy impact human immunodeficiency virus (HIV) serological assay sensitivity, leading to more false-negative test results in HIV diagnosis. J Infect Dis. 2020; 222(10):1660-9. https://doi.org/10.1093/infdis/jiaa271
de Souza MS, Pinyakorn S, Akapirat S, Pattanachaiwit S, Fletcher JLK, Chomchey N, et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology. Clin Infect Dis. 2016; 63(4):555-61. https://doi.org/10.1093/cid/ciw365
Heckathorn DD. Respondent-driven sampling: A new approach to the study of hidden populations. Soc Probl. 1997; 44(2):174-99. https://doi.org/10.2307/3096941
Heckathorn DD, Semaan S, Broadhead RS, Hughes JJ. Extensions of respondent-driven sampling: A new approach to the study of injection drug users aged 18-25. AIDS Behav. 2002; 6(1):55-67.
Heckathorn DD. Respondent-driven sampling II: Deriving valid population estimates from chain referral samples of hidden populations. Soc Probl. 2002; 49(1):11-34. https://doi.org/10.1525/sp.2002.49.1.11
Salganik MJ, Heckathorn DD. Sampling and estimation in hidden populations using respondent-driven sampling. Sociol Methodol. 2004; 34:193-239. https://doi.org/10.1111/j.0081-1750.2004.00152.x
Volz E, Heckathorn DD. Probability based estimation theory for respondent driven sampling. J Off Stat. 2008; 24(1):79-97.
Cohen JA. Coefficient of agreement for nominal scales. Educ Psychol Meas. 1960; 20(1):37-46. https://doi.org/10.1177/001316446002000104
Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1990. Inter-rather agreement; p. 403-9.
Elliott T, Sanders EJ, Doherty M, Ndung’u T, Cohen M, Patel P et al. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: A scoping review. J Int AIDS Soc. 2019; 22(12): e25419. https://doi.org/10.1002/jia2.25419.
Vieira KF, Shitara ES, Mendes ME, Sumita NM. A utilidade dos indicadores da qualidade no gerenciamento de laboratórios clínicos. J Bras Patol Med Lab. 2011; 47(3): 201-10.
Castejon MJ, Yamashiro R, Oliveira CAF, Brígido LFM, Generoso IP, Veras MAS et al. Performance of rapid tests compared to conventional tests used for HIV diagnosis. J Bras Patol Med Lab. 2018; 54(6):364-71. https://doi.org/10.5935/1676-2444.20180058
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016; 375(9):830-9. https://doi.org/10.1056/NEJMoa1600693
Wang L , Hong W, Zhu W, Lu L, Yang Z, Zhao F et al. Efficacy of early antiretroviral therapy 36 hours after HIV infection in one blood donor. Transfusion. 2020; 60(7):1633-8. https://doi.org/10.1111/trf.15822
Manak MM, Jagodzinski LL, Shutt A, Malia JA, Leos M, Ouellette J et al. Decreased seroreactivity in individuals initiating antiretroviral therapy during acute HIV infection. J Clin Microbiol. 2019; 57(10): e00757-19. https://doi.org/10.1128/JCM.00757-19
Ferreira Junior OC. Programa Sentinela para Vigilância Epidemiológica da infecção pelo HIV-2 no Brasil. TC 288/2013. [Internet] [Acesso em: 2021, dez 22] Disponível em: http://www.aids.gov.br/pt-br/ct/tc-2882013
Guan M. Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus. Clin Vaccine Immunol. 2007; 14(6): 649-59. https://doi.org/10.1128/CVI.00393-06
Guan M. Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus. Clin Vaccine Immunol. 2007; 14(6): 649-59. https://doi.org/10.1128/CVI.00393-06
Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis. 2005; 40(6): 868-73. https://doi.org/10.1086/428127
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Márcia Jorge Castejon, Carmem Aparecida de Freitas Oliveira, Luís Fernando de Macedo Brígido , Rosemeire Yamashiro, Katia Cristina Bassichetto , Norberto Camilo Campos , Elaine Lopes de Oliveira, Ana Rita Coimbra Motta Castro , Inês Dourado , Laio Magno, Roberto José de Carvalho da Silva , Maria Amélia de Sousa Mascena Veras